Vergelijking

Elamipretide vs. Nafarelin

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

736992-21-5

geen gegevens

Molecuulmassa

639.8 g/mol

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

D-Arg-Dmt-Lys-Phe-NH2

geen gegevens

Werkingsmechanisme

Elamipretide

Elamipretide is a cell-permeable tetrapeptide with alternating aromatic and basic residues that selectively concentrates on cardiolipin — a phospholipid found almost exclusively in the inner mitochondrial membrane that is important for cristae curvature and the organisation of the respiratory-chain complexes. By binding cardiolipin, elamipretide is proposed to stabilise cristae architecture, support electron transport and ATP production, and reduce the formation of reactive oxygen species. These mechanistic models derive largely from cell and animal models and biophysical work; the extent to which they explain clinical efficacy in humans is, given the mixed trial results, a matter of ongoing research.

Nafarelin

Nafarelin is a potent GnRH agonist: after an initial stimulation ('flare'), continuous receptor occupancy leads to downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Elamipretide	Nafarelin
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Elamipretide

Volledige vermelding →

Nafarelin

Volledige vermelding →

Frequently asked questions

What is the difference between Elamipretide and Nafarelin?: Elamipretide is classified as "Onderzoek (overig)", while Nafarelin is classified as "Onderzoek (overig)". Elamipretide: Elamipretide (SS-31, MTP-131, formerly Bendavia) is a synthetic, mitochondria-targeting tetrapeptide (sequence D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane and is proposed to stabilise cristae structure and support mitochondrial bioenergetics. It was investigated clinically by Stealth BioTherapeutics across several indications, including primary mitochondrial myopathy, Barth syndrome, heart failure, and dry age-related macular degeneration (geographic atrophy). The trial record is mixed, with several pivotal studies missing their primary endpoints. In September 2025 elamipretide (brand name Forzinity) received accelerated FDA approval in the United States solely for the ultra-rare Barth syndrome; for all other investigated indications it remains investigational and it is not approved as a medicine outside the United States. Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Elamipretide or Nafarelin?: The highest available evidence level is "Humane RCT" for Elamipretide and "Humane RCT" for Nafarelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Elamipretide and Nafarelin in Germany and the United States?: Duitsland: Elamipretide — Niet goedgekeurd, Nafarelin — Op recept. Verenigde Staten: Elamipretide — Op recept, Nafarelin — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Elamipretide

Nafarelin

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Elamipretide and Nafarelin?

Elamipretide is classified as "Onderzoek (overig)", while Nafarelin is classified as "Onderzoek (overig)". Elamipretide: Elamipretide (SS-31, MTP-131, formerly Bendavia) is a synthetic, mitochondria-targeting tetrapeptide (sequence D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane and is proposed to stabilise cristae structure and support mitochondrial bioenergetics. It was investigated clinically by Stealth BioTherapeutics across several indications, including primary mitochondrial myopathy, Barth syndrome, heart failure, and dry age-related macular degeneration (geographic atrophy). The trial record is mixed, with several pivotal studies missing their primary endpoints. In September 2025 elamipretide (brand name Forzinity) received accelerated FDA approval in the United States solely for the ultra-rare Barth syndrome; for all other investigated indications it remains investigational and it is not approved as a medicine outside the United States. Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Elamipretide or Nafarelin?

The highest available evidence level is "Humane RCT" for Elamipretide and "Humane RCT" for Nafarelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Elamipretide and Nafarelin in Germany and the United States?

Duitsland: Elamipretide — Niet goedgekeurd, Nafarelin — Op recept. Verenigde Staten: Elamipretide — Op recept, Nafarelin — Op recept. These are factual summaries with source and review date on the individual pages.